- Conditions
- Dry Eye Syndromes, Dry Eye
- Interventions
- RGN-259, Placebo
- Drug
- Lead sponsor
- ReGenTree, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1033–1056
of 5,305
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Kidney Disease
- Interventions
- PRT-201, Placebo
- Drug
- Lead sponsor
- Proteon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 23
- States / cities
- San Diego, California • San Francisco, California • Chicago, Illinois + 18 more
- Conditions
- Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
- Interventions
- Tipifarnib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 171
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
- Conditions
- Advanced Cancer
- Interventions
- RBS2418, Pembrolizumab, Other approved anti-cancer therapy
- Drug
- Lead sponsor
- Riboscience, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 11 more
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm
- Interventions
- Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 108
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 84 more
- Conditions
- Heart Failure
- Interventions
- Baxdrostat and dapagliflozin, Placebo and dapagliflozin
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 11,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 217
- States / cities
- Birmingham, Alabama • Centreville, Alabama • Fairhope, Alabama + 188 more
- Conditions
- Psoriasis Vulgaris
- Interventions
- Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%, Enstilar® foam (LEO Pharma Inc.), Placebo of Calcipotriene/ betamethasone dipropionate topical foam
- Drug · Other
- Lead sponsor
- Glenmark Pharmaceuticals Ltd. India
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 494 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 30
- States / cities
- Encinitas, California • Fountain Valley, California • San Diego, California + 24 more
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
- Interventions
- Sitravatinib, Nivolumab, Pembrolizumab, Enfortumab vedotin
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Irvine, California • Aurora, Colorado + 30 more
- Conditions
- Dermatitis, Contact
- Interventions
- TRUE Test allergens Fragrance Mix and Thimerosol
- Biological
- Lead sponsor
- Allerderm
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • Shawnee Mission, Kansas • Louisville, Kentucky + 1 more
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- Bimatoprost SR, Sham Bimatoprost SR, Selective Laser Trabeculoplasty, Sham Selective Laser Trabeculoplasty
- Drug · Procedure
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 51
- States / cities
- Dothan, Alabama • Glendale, Arizona • Phoenix, Arizona + 43 more
- Conditions
- Advance Care Planning, Advance Directives, Terminal Illness, Chronic Illness, Communication
- Interventions
- Hello (serious game), The Conversation Project (CP) Starter Kit, Table Topics (general conversation game)
- Behavioral · Other
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 79
- States / cities
- Athens, Alabama • Kingman, Arizona • Show Low, Arizona + 70 more
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Ginger exosomes, Aloe exosomes, Placebo
- Other
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Sarcoma
- Interventions
- dactinomycin, filgrastim, pegfilgrastim, sargramostim, cyclophosphamide, irinotecan hydrochloride, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 49 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 209
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
- Interventions
- Epanova® (omega-3 carboxylic acids), corn oil control
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 13,078 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 229
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 183 more
- Conditions
- Carcinoma, Renal Cell, Kidney Neoplasms
- Interventions
- Interferon Alfa, CCI-779, Interferon Alfa and CCI-779
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 626 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 48
- States / cities
- Little Rock, Arkansas • La Verne, California • Los Angeles, California + 44 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Pazopanib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 662 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Orange, California • Jacksonville, Florida + 12 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Abatacept, Placebo, Prednisone
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Long Beach, California • Los Angeles, California + 9 more
- Conditions
- Carcinoma
- Interventions
- Paclitaxel, Carboplatin, Bevacizumab, Erlotinib, Treatment determined by physician
- Drug · Other
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 21
- States / cities
- Huntsville, Alabama • Fort Myers, Florida • Jacksonville, Florida + 18 more
- Conditions
- Spasticity
- Interventions
- SPARC1104 modified dose regimen I, SPARC1104 modified dose regimen II, SPARC1104 modified dose regimen III
- Drug
- Lead sponsor
- Sun Pharma Advanced Research Company Limited
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 51
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 47 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Elritercept, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 25
- States / cities
- Duarte, California • Glendale, California • La Jolla, California + 21 more
- Conditions
- High-grade Gliomas (HGG)
- Interventions
- Dexamethasone, Azeliragon
- Drug
- Lead sponsor
- Akshitkumar MIstry
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Louisville, Kentucky
- Conditions
- Urinary Incontinence, Stress
- Interventions
- SS-RBX
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 89
- States / cities
- Anchorage, Alaska • Sun City, Arizona • Tucson, Arizona + 78 more
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- asparaginase, cytarabine, daunorubicin hydrochloride, methotrexate, therapeutic hydrocortisone, thioguanine
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 209
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- B-cell Non Hodgkin Lymphoma
- Interventions
- ARC-02, Rituximab
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Louisville, Kentucky • New York, New York + 4 more